TEAM
CURRENT MEMBERS
Postdoctoral researchers
Development of a primary hepatocyte spheroid culture system for the detection of chemical-induced cholestatic liver injury
To be completed in 2021
Promoter: Mathieu Vinken
Dr. Pharm. Vânia Vilas-Boas
Doctoral researchers
The role of connexins, pannexins and their channels in cholestasis
To be completed in 2022
Promoter: Mathieu Vinken
Dr. Pharm. Alanah Pieters
Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury
To be completed in 2022
Promoter: Mathieu Vinken
Dr. Pharm. Bruna dos Santos Rodrigues
Development and testing of new inhibitors of Cx43 hemichannels and Panx1 channels
To be completed in 2024
Promoter: Mathieu Vinken
Dr. M. Sci. Andrés Tabernilla
Pharm. Axelle Cooreman
The role of connexins, pannexins and their channels in cholestasis
To be defended in 2022
Promoters: Mathieu Vinken, Pieter Annaert
Pharm. Eva Gijbels
Characterization of new mechanisms of cholestasis as the basis for animal-free prediction of drug-induced liver injury
To be defended in 2022
Promoters: Mathieu Vinken, Lindsey Devisscher
Co-promoter: Tamara Vanhaecke
M. Sci Emma Gustafson
Development and testing of a repeated dose toxicity ontology model for chemical risk assessment purposes: liver effects as a case study
To be defended in 2022
Promoters: Mathieu Vinken, Tamara Vanhaecke
M. Sci Kaat Leroy
The role of connexins, pannexins and their channels in liver cancer
To be defended in 2022
Promoter: Mathieu Vinken
Co-promoter: Bruno Cogliati
Pharm. Raf Van Campenhout
Development of nanobody-based inhibitors of connexin hemichannels and pannexin channels as novel therapeutics for the treatment of liver disease
To be defended in 2022
Promoters: Mathieu Vinken, Nick Devoogdt, Serge Muyldermans
M. Pharm. Sci. Anne Caufriez
Development and in vitro testing of peptidomimetic-based inhibitors of pannexin1 channels
To be defended in 2023
Promoters: Mathieu Vinken, Steven Ballet
Scientific collaborators
.jpg)
The role of connexin43 hemichannels and pannexin1 channels in liver cancer
To be defended in 2024 (University of São Paulo-Brazil)
Promoters: Bruno Cogliati, Mathieu Vinken
M. Sci. Cícero Júlio Silva Costa
Development of nanobody-based inhibitors of connexin43 hemichannels
To be completed in 2021
Promoter: Mathieu Vinken
M. Sci. Ana Rita Coelho Gomes
Technicians
Dinja De Win
Tâmara Prandini
Manon Wery
FORMER TEAM MEMBERS
Dr. M. Sci. Sara Crespo-Yanguas
Dr. Pharm. Michaël Maes
Dr. Pharm. Joost Willebrords
Miss Tineke Vanhalewyn
FINISHED POSTDOCTORAL PROJECTS
Role of connexin and pannexin (hemi)channels in liver cancer
Tereza Cristina da Silva: completed 31/03/2017
Promoters: Mathieu Vinken, Bruno Cogliati
Role of connexin and pannexin (hemi)channels in hepatitis
Isabel Veloso Alves Pereira: completed 31/03/2017
Promoters: Mathieu Vinken, Bruno Cogliati
FINISHED DOCTORAL PROJECTS
Evaluation of carcinogen-modified global gene expression profiles in liver-based in vitro models with focus on primary hepatocyte cultures
Tatyana Doktorova: defended 16/03/2012
Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers
Development of a differentiated hepatic in vitro system for long-term pharmaco-toxicological studies based on (epi)genetic modification of primary hepatocytes
Eva Ramboer: defended 15/10/2015
Promoters: Mathieu Vinken, Tamara Vanhaecke, Vera Rogiers
The role of connexins, pannexins and their channels in acute liver failure
Michaël Maes: defended 17/10/2017
Promoters: Mathieu Vinken, Bruno Cogliati
The role of connexins, pannexins and their channels in non-alcoholic steatohepatitis
Joost Willebrords: defended 29/01/2018
Promoters: Mathieu Vinken, Bruno Cogliati
The role of connexins, pannexins and their channels in liver fibrosis
Sara Crespo Yanguas: defended 25/10/2018
Promoters: Mathieu Vinken, Bruno Cogliati
Connexin43 hemichannels as druggable targets for future anti-seizure medication
Laura Walrave: defended 24/01/2019
Promoter: Ilse Smolders
Co-promoters: Mathieu Vinken, Luc Leybaert
© 2023 by InVitroTox Consulting.
Proudly created using Wix.com
